Monlutenca (Lutetium (177lu) Chloride)

Lutetium‑177 chloride emits beta particles that travel short distances, causing DNA damage in cells that have taken up the compound. When linked to a tumor‑specific ligand, the radio‑isotope concentrates in malignant tissue, allowing localized radiation while limiting exposure to surrounding healthy cells.

The dose of Monlutenca is individualized. A qualified prescriber determines the activity (in megabecquerels) and schedule based on the patient’s disease characteristics, body weight, renal function, and prior therapies.

Monlutenca is contraindicated in pregnancy because the radiation can harm the developing fetus. Women of child‑bearing potential should use effective contraception, and breastfeeding should be discontinued before treatment. The safety profile in lactating mothers has not been established.

To order Monlutenca, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Monlutenca contains Lutetium‑177, which emits beta particles with a tissue penetration range suitable for treating small‑to‑moderate sized tumors. Compared with Yttrium‑90‑based agents, Lutetium‑177 provides a shorter radiation path and lower whole‑body dose, often resulting in a more favorable safety profile for certain indications.

Monlutenca should be stored at ambient temperature, below 25 °C, in its original sealed container. Protect the product from direct sunlight, moisture and physical shock. Follow all local regulations for handling radioactive materials and use appropriate shielding during preparation.

Monlutenca is administered intravenously by a qualified healthcare professional. The solution is typically infused over a short period under controlled conditions, with monitoring for immediate adverse reactions and post‑infusion observation as required.

The most serious risks include severe bone‑marrow suppression leading to prolonged neutropenia or thrombocytopenia, significant renal toxicity, and the rare possibility of secondary malignancies due to radiation exposure. Patients should be closely monitored for hematologic and renal parameters throughout therapy.

Monlutenca should not be given to pregnant women, nursing mothers, or patients with severe renal impairment (e.g., creatinine clearance below the recommended threshold). Individuals receiving other high‑dose radiopharmaceuticals or myelosuppressive chemotherapy should also be evaluated carefully before treatment.